Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 19,500 | |||
5 mg | 在庫あり | ¥ 45,500 | |||
10 mg | 在庫あり | ¥ 75,500 | |||
25 mg | 在庫あり | ¥ 128,000 | |||
50 mg | 在庫あり | ¥ 181,000 | |||
100 mg | 在庫あり | ¥ 257,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 52,000 |
説明 | RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein. |
ターゲット&IC50 | BRD4 BD1:1.16 μM, BRD2 BD1:3.76 μM, BRD4 BD2:0.02 μM, BRD3 BD2:0.05 μM, BRD3 BD1:2.34 μM, BRDT BD1:2.69 μM, BRD2 BD2:0.08 μM |
In vitro | RVX-297 suppressed IL-6 gene induction in human U937 macrophages, mouse primary B cells isolated from the spleen, mouse BMDMs, and THP-1 monocytes in a dose-dependent manner[2]. |
In vivo | In the rCIA model, RVX-297 treatment had a substantial impact on cytokine gene expression; expressions of IL-1β, RANKL, MMP3, and MMP13 were all significantly decreased in the ankle joints of arthritic rats after RVX-297 treatment at 75 mg/kg BID versus vehicle-treated arthritic controls[2]. |
別名 | RVX297 |
分子量 | 423.5 |
分子式 | C24H29N3O4 |
CAS No. | 1044871-04-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/ml(94.45 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RVX-297 1044871-04-6 Chromatin/Epigenetic Epigenetic Reader Domain autoimmunity proinflammatory RVX 297 immune inhibit mediator inflammatory Inhibitor selectivity acute cell RVX297 arthritis inhibitor